MapLight Therapeutics stock
MPLTNASDAQMapLight Therapeutics, Inc., HealthcareISIN US56565P1030
33Score 33 out of 100, Weak
Price and trend
39 / 100
Price history
−51% in one yearThe chart shows daily closes over 1 year, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 65% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 40).
The price is 82% below its 52-week high. Largest decline in 1 year: 84% (July 2026 to November 2026).
Chart figures for advanced users
- SMA 50$9.46
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.02
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)40
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.22
- The lowest closing price of the last twelve months.
- Resistance$39.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- MapLight Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $301.31M, is number 287 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 33 out of 100 (Weak): rank 662 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $305.1M, financial debt $5.8M.Stability 69
Weaknesses
- Volatile share priceVolatility 113% a year over the last 12 months.Stability 69
- Loss-makingLoss of $161.15M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$138.61M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 32 to 33.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 3 Dec 2026in 21 days
- Last reported
- 18 Sep 2026EPS reported −$1.32 (expected −$1.35)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$4.950.0%
- Revenue
- $00.0%
- Earnings per share
- −$3.910.0%
- Revenue
- $16.67M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $65.54M in total. 6 insiders sold, $12.71M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kreitzer AnatolSale
15 Oct 2026, Chief Discovery Officer
- Shares
- 12,248
- Price
- $7.84
- Value
- $96,024
- Gillis JonathanSale
15 Oct 2026, CAO and Interim CFO
- Shares
- 10,167
- Price
- $8.08
- Value
- $82,149
- Lillie James WoodruffSale
15 Oct 2026, Chief Scientific Officer
- Shares
- 11,513
- Price
- $8.08
- Value
- $93,025
Show 28 more
- Hanson KristopherSale
15 Oct 2026, General Counsel
- Shares
- 9,020
- Price
- $8.08
- Value
- $72,882
- Foff Erin PennockSale
15 Oct 2026, Chief Medical Officer
- Shares
- 15,355
- Price
- $8.08
- Value
- $124,068
- Kroeger Christopher A.Sale
15 Oct 2026, Chief Executive Officer
- Shares
- 73,691
- Price
- $8.08
- Value
- $595,423
- Hanson KristopherSale
16 Sept 2026, General Counsel
- Shares
- 16,509
- Price
- $11.67
- Value
- $192,660
- Catalyst4, Inc.Purchase
14 Aug 2026, Major holder
- Shares
- 4,400,000
- Price
- $11.38
- Value
- $50.07M
- Lillie James WoodruffSale
3 Aug 2026, Chief Scientific Officer
- Shares
- 22,082
- Price
- $12.54
- Value
- $276,908
- Catalyst4, Inc.Purchase
30 Jul 2026, Major holder
- Shares
- 1,000,000
- Price
- $13.00
- Value
- $13M
- Catalyst4, Inc.Purchase
29 Jul 2026, Major holder
- Shares
- 3,000
- Price
- $12.63
- Value
- $37,890
- Catalyst4, Inc.Purchase
28 Jul 2026, Major holder
- Shares
- 206,225
- Price
- $11.04
- Value
- $2.28M
- Cox TroyPurchase
28 Jul 2026, Board
- Shares
- 15,620
- Price
- $9.52
- Value
- $148,702
- Gillis JonathanSale
17 Jul 2026, CAO and Interim CFO
- Shares
- 18,469
- Price
- $37.60
- Value
- $694,463
- Kreitzer AnatolSale
17 Jul 2026, Chief Discovery Officer
- Shares
- 17,173
- Price
- $37.60
- Value
- $645,719
- Kroeger Christopher A.Sale
17 Jul 2026, Chief Executive Officer
- Shares
- 16,779
- Price
- $37.90
- Value
- $635,924
- Lillie James WoodruffSale
17 Jul 2026, Chief Scientific Officer
- Shares
- 2,077
- Price
- $37.90
- Value
- $78,718
- Hanson KristopherSale
17 Jul 2026, General Counsel
- Shares
- 1,130
- Price
- $37.90
- Value
- $42,827
- Foff Erin PennockSale
17 Jul 2026, Chief Medical Officer
- Shares
- 3,656
- Price
- $37.90
- Value
- $138,562
- Gillis JonathanSale
16 Jul 2026, CAO and Interim CFO
- Shares
- 8,455
- Price
- $36.80
- Value
- $311,112
- Kreitzer AnatolSale
16 Jul 2026, Chief Discovery Officer
- Shares
- 9,056
- Price
- $36.80
- Value
- $333,235
- Kroeger Christopher A.Sale
16 Jul 2026, Chief Executive Officer
- Shares
- 69,082
- Price
- $36.79
- Value
- $2.54M
- Lillie James WoodruffSale
16 Jul 2026, Chief Scientific Officer
- Shares
- 8,547
- Price
- $36.79
- Value
- $314,412
- Hanson KristopherSale
16 Jul 2026, General Counsel
- Shares
- 8,118
- Price
- $36.78
- Value
- $298,616
- Foff Erin PennockSale
16 Jul 2026, Chief Medical Officer
- Shares
- 15,047
- Price
- $36.77
- Value
- $553,334
- Gillis JonathanSale
15 Jul 2026, CAO and Interim CFO
- Shares
- 10,055
- Price
- $36.51
- Value
- $367,093
- Kreitzer AnatolSale
15 Jul 2026, Chief Discovery Officer
- Shares
- 10,055
- Price
- $36.49
- Value
- $366,940
- Kroeger Christopher A.Sale
15 Jul 2026, Chief Executive Officer
- Shares
- 61,778
- Price
- $36.69
- Value
- $2.27M
- Lillie James WoodruffSale
15 Jul 2026, Chief Scientific Officer
- Shares
- 7,643
- Price
- $36.70
- Value
- $280,506
- Hanson KristopherSale
15 Jul 2026, General Counsel
- Shares
- 7,260
- Price
- $36.70
- Value
- $266,427
- Foff Erin PennockSale
15 Jul 2026, Chief Medical Officer
- Shares
- 28,455
- Price
- $36.64
- Value
- $1.04M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at MapLight Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Enanta PharmaceuticalsENTA $337.85M28
- Autolus TherapeuticsAUTL $330.04M31
- OcugenOCGN $325.87M36
- Turn TherapeuticsTTRX $320.99M45
- Vicore Pharma HoldingVICO.ST $318.18M38
- Kyverna TherapeuticsKYTX $316.64M28
- EvommuneEVMN $312.84M33
- Cabaletta BioCABA $312.79M28
ETFs that hold MapLight Therapeutics
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.00% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.